Chapter 1
Epidemiology, Classification, and Clinical Impact of Ventricular Tachycardia/Ventricular Fibrillation
John A. Camm MD,
Amin Al-Ahmad MD,
David S. Cannom MD,
Jeronimo Farré MD,
Mark E. Josephson MD,
Hein J. J. Wellens MD,
John A. Camm MD
Cardiac and Vascular Sciences, St. George' Hospital Medical School, London, UK
Search for more papers by this authorAmin Al-Ahmad MD
Cardiac Arrhythmia Service, Stanford University Medical School, Stanford, CA, USA
Search for more papers by this authorDavid S. Cannom MD
Good Samaritan Hospital, Los Angeles, CA, USA
Search for more papers by this authorJeronimo Farré MD
Department of Cardiology, Fundación Jiménez Díaz, Madrid, Spain
Search for more papers by this authorMark E. Josephson MD
Department of Cardiology, Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA, USA
Search for more papers by this authorHein J. J. Wellens MD
Cardiovascular Research Institute, Maastricht, The Netherlands
Search for more papers by this authorJohn A. Camm MD,
Amin Al-Ahmad MD,
David S. Cannom MD,
Jeronimo Farré MD,
Mark E. Josephson MD,
Hein J. J. Wellens MD,
John A. Camm MD
Cardiac and Vascular Sciences, St. George' Hospital Medical School, London, UK
Search for more papers by this authorAmin Al-Ahmad MD
Cardiac Arrhythmia Service, Stanford University Medical School, Stanford, CA, USA
Search for more papers by this authorDavid S. Cannom MD
Good Samaritan Hospital, Los Angeles, CA, USA
Search for more papers by this authorJeronimo Farré MD
Department of Cardiology, Fundación Jiménez Díaz, Madrid, Spain
Search for more papers by this authorMark E. Josephson MD
Department of Cardiology, Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA, USA
Search for more papers by this authorHein J. J. Wellens MD
Cardiovascular Research Institute, Maastricht, The Netherlands
Search for more papers by this authorBook Editor(s):Andrea Natale MD, FACC, FHRS,
Antonio Raviele MD, FESC,
Andrea Natale MD, FACC, FHRS
Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, TX, USA
Division of Cardiology, Stanford University, CA, USA
Case Western Reserve University, Cleveland, OH, USA
EP Services, California Pacific Medical Center, San Francisco, CA, USA
Search for more papers by this authorAntonio Raviele MD, FESC
Cardiovascular Department, Arrhythmia Center & Center for Atrial Fibrillation, Ospedale dell'Angelo, Venice-Mestre, Italy
Search for more papers by this authorFirst published: 11 September 2009
Summary
This chapter contains sections titled:
-
Epidemiology of ventricular tachycardia and ventricular fibrillation
-
Classification of ventricular tachycardia and ventricular fibrillation
-
Classification according to the duration of ventricular arrhythmias
-
Classification according to QRS morphologies
-
Classification according to clinical characteristics of ventricular tachycardia
-
Conditions associated with ventricular tachycardia/ventricular fibrillation
-
Coronary heart disease as the most frequent cause of ventricular tachycardia/ventricular fibrillation and sudden cardiac death
-
Natural history of patients with sustained ventricular arrhythmias and ischemic and nonischemic cardiomyopathy
-
Mechanisms of ventricular arrhythmias in ischemic cardiomyopathy
-
Mechanisms of ventricular arrhythmias in nonischemic dilated cardiomyopathy
-
Impact of sudden cardiac death in the natural history of ischemic and nonischemic dilated cardiomyopathy with a history of heart failure
-
The different natural history of ischemic and nonischemic dilated cardiomyopathy patients
-
Arrhythmogenic right ventricular cardiomyopathy: its role in sudden cardiac death and mechanisms of ventricular arrhythmias related to this entity
-
Hypertrophic cardiomyopathy and sudden cardiac death with special emphasis on athletes
-
Congenital heart disease
-
Catecholaminergic polymorphic ventricular tachycardia
-
The Brugada syndrome
-
The long QT syndrome
-
Drug-induced ventricular arrhythmias
-
Ventricular tachycardia/ventricular fibrillation clinical presentation: hemodynamically stable and hemodynamically unstable
-
References
References
- Hiss RG, Lamb LE, Allen MF. Electrocardiographic findings in 67,375 asymptomatic subjects. X. Normal values. Am J Cardiol 1960; 6: 200–231.
- Hinkle LE, Jr., Carver ST, Stevens M. The frequency of asymptomatic disturbances of cardiac rhythm and conduction in middle-aged men. Am J Cardiol 1969; 24: 629–650.
- Kennedy HL, Whitlock JA, Sprague MK, Kennedy LJ, Buckingham TA, Goldberg RJ. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985; 312: 193–197.
- Engstrom G, Hedblad B, Janzon L, Juul-Moller S. Ventricular arrhythmias during 24-h ambulatory ECG recording: incidence, risk factors and prognosis in men with and without a history of cardiovascular disease. J Intern Med 1999; 246: 363–372.
- Jouven X, Zureik M, Desnos M, Courbon D, Ducimetiere P. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med 2000; 343: 826–833.
- Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003; 348: 781–790.
- Hinkle LE, Carver ST, Argyros DC. The prognostic significance of ventricular premature contractions in healthy people and in people with coronary heart disease. Acta Cardiol Suppl 1974; 18: 5–32.
- Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980–2000. JAMA 2002; 288: 3008–3013.
- Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 2006; 114: 1088–1132.
- Gillum RF. Geographic variation in sudden coronary death. Am Heart J 1990; 119: 380–389.
- Engdahl J, Bang A, Lindqvist J, Herlitz J. Time trends in long-term mortality after out-of-hospital cardiac arrest, 1980 to 1998, and predictors for death. Am Heart J 2003; 145: 826–833.
- Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104: 2158–2163.
- Corwin LE, Wolf PA, Kannel WB, McNamara PM. Accuracy of death certification of stroke: the Framingham Study. Stroke 1982; 13: 818–821.
- Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004; 44: 1268–1275.
- Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006; 47: 1161–1166.
- Bardy GH, Lee KL, Mark DB, et al. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med 2008; 358: 1793–1804.
- Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation 2002; 106: 309–312.
- Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87: 312–322.
- Solomon SD, Zelenkofske S, McMurray JJ, et al. Valsartan in Acute Myocardial Infarction Trial I. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581–2588.
- Avezum A, Piegas LS, Goldberg RJ, et al. Magnitude and prognosis associated with ventricular arrhythmias in patients hospitalized with acute coronary syndromes [from the GRACE Registry]. Am J Cardiol 2008; 102: 1577–1582.
- Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Podrid PJ. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction [TIMI] Phase II trial. J Am Coll Cardiol 1993; 22: 1773–1779.
- Kannel WB, Thomas HE, Jr. Sudden coronary death: the Framingham study. Ann NY Acad Sci 1982; 382: 3–21.
- Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. Circulation 2003; 107: 2096–2101.
- Kaikkonen KS, Kortelainen ML, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006; 114: 1462–1467.
- Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation 1998; 97: 155–160.
-
Friedlander Y, Siscovick DS, Arbogast P, et al. Sudden death and myocardial infarction in first degree relatives as predictors of primary cardiac arrest. Atherosclerosis 2002; 162: 211–216.
10.1016/S0021-9150(01)00701-8 Google Scholar
- Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999; 99: 1978–1983.
- Becker LB, Han BH, Meyer PM, et al. Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project. N Engl J Med 1993; 329: 600–606.
- Russo AM, Hafley GE, Lee KL, et al. Multicenter UnSustained Tachycardia Trial I. Racial differences in outcome in the Multicenter UnSustained Tachycardia Trial [MUSTT]: a comparison of whites versus blacks. Circulation 2003; 108: 67–72.
- Vorobiof G, Goldenberg I, Moss AJ, Zareba W, McNitt S. Effectiveness of the implantable cardioverter defibrillator in blacks versus whites [from MADIT-II]. Am J Cardiol 2006; 1383; 98: 1383–1386.
- Shedd OL, Sears SF, Jr., Harvill JL, et al. The World Trade Center attack: increased frequency of defibrillator shocks for ventricular arrhythmias in patients living remotely from New York City. J Am Coll Cardiol 2004; 44: 1265–1267.
- Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol 2007; 18: 181–184.
- Goldenberg I, Moss AJ, McNitt S, et al. Multicenter automatic defibrillator implantation trial III. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J Cardiovascul Electrophysiol 2006; 17: 931–936.
- Steinberg JS, Arshad A, Kowalski M, et al. Increased incidence of life-threatening ventricular arrhythmias in implantable defibrillator patients after the World Trade Center attack. J Am Coll Cardiol 2004; 44: 1261–1264.
- Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham heart study. Circulation 2004; 110: 522–527.
- Bunch TJ, White RD. Trends in treated ventricular fibrillation in out-of-hospital cardiac arrest: ischemic compared to non-ischemic heart disease. Resuscitation 2005; 67: 51–54.
- Bunch TJ, White RD, Friedman PA, Kottke TE, Wu LA, Packer DL. Trends in treated ventricular fibrillation out-of-hospital cardiac arrest: a 17-year population-based study. Heart Rhythm 2004; 1: 255–259.
- Youngquist ST, Kaji AH, Niemann JT. Beta-blocker use and the changing epidemiology of out-of-hospital cardiac arrest rhythms. Resuscitation 2008; 76: 376–380.
- Olshansky B, Wood F, Hellkamp AS, et al. Investigators SC-H. Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial [SCD-HeFT]. Am Heart J 1089; 153: 1089–1094.
-
Anonymous. Metoprolol in acute myocardial infarction. Arrhythmias. The MIAMI Trial Research Group. Am J Cardiol 1985; 56: 22.
10.1016/0002-9149(85)90481-3 Google Scholar
- Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation 2004; 110: 1413–1417.
- Coleman CI, Kluger J, Bhavnani S, et al. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dys-function. Heart Rhythm 2008; 5: 507–510.
-
Lerman BB, Stein KM, Markowitz SM, Mittal S. Ventricular tachycardia in patients with stucturally normal hearts. In: Zipes DP, ed. Cardiac Electrophysiology: From Cell to Bedside. Saunders, Philadelphia, 2004: 668–682.
10.1016/B0-7216-0323-8/50075-0 Google Scholar
- Huelsing DJ, Spitzer KW, Pollard AE. Spontaneous activity induced in rabbit Purkinje myocytes during coupling to a depolarized model cell. Cardiovasc Res 2003; 59: 620–627.
- Spitzer KW, Pollard AE, Yang L, Zaniboni M, Cordeiro JM, Huelsing DJ. Cell-to-cell electrical interactions during early and late repolarization. J Cardiovasc Electrophysiol 2006; 17: S8–S14.
- Lerman BB. Mechanism of outflow tract tachycardia. Heart Rhythm 2007; 4: 973–976.
- Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 2004; 84: 431–488.
- de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988; 77: 589–606.
- de Bakker JM, Coronel R, Tasseron S, et al. Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol 1990; 15: 1594–1607.
- de Bakker JM, van Capelle FJ, Janse MJ, et al. Slow conduction in the infarcted human heart. ‘Zigzag’ course of activation. Circulation 1993; 88: 915–926.
- Viskin S, Rosso R, Rogowski O, Belhassen B. The “short-coupled” variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol 2005; 16: 912–916.
- Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol 1993; 4: 356–368.
- Miller JM, Marchlinski FE, Buxton AE, Josephson ME. Relationship between the 12-lead electrocardiogram during ventricular tachycardia and endocardial site of origin in patients with coronary artery disease. Circulation 1988; 77: 759–766.
- Josephson ME, Waxman HL, Cain ME, Gardner MJ, Buxton AE. Ventricular activation during ventricular endocardial pacing. II. Role of pace-mapping to localize origin of ventricular tachycardia. Am J Cardiol 1982; 50: 11–22.
- Bazan V, Bala R, Garcia FC, et al. Twelve-lead ECG features to identify ventricular tachycardia arising from the epicardial right ventricle. Heart Rhythm 2006; 3: 1132–1139.
- Josephson ME. Clinical Cardiac Electrophysiology: Technique and Interpretation Wolters Kluwer/Lippincott Williams & Wilkins, 4th edn. Philadelphia, 2008.
- Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Eng J Med 1991; 324: 781–788.
- Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) investigators. Circulation 2000; 101: 40–46.
- O'Neill JO, Young JB, Pothier CE, Lauer MS. Severe frequent ventricular ectopy after exercise as a predictor of death in patients with heart failure. J Am Coll Cardiol 2004; 44: 820–826.
- Investigators. TC. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest [the CASCADE Study]. Am J Cardiol 1993; 72: 280–287.
- Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg [CASH]. Circulation 2000; 102: 748–754.
- Anonymous. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators [AVID] Investigators. N Engl J Med 1997; 337: 1576–1583.
- Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study [CIDS]: a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297–1302.
- Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur Heart J 2000; 21: 2071–2078.
- Hallstrom AP, McAnulty JH, Wilkoff BL, et al. Antiarrhythmics Versus Implantable Defibrillator Trial I. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. J Am Coll Cardiol 2001; 37: 1093–1099.
- Brodsky MA, McAnulty J, Zipes DP, Baessler C, Hallstrom AP. A history of heart failure predicts arrhythmia treatment efficacy: data from the Antiarrythmics versus Implantable Defibrillators [AVID] study. Am Heart J 2006; 152: 724–730.
- Callans DJ. Patients with hemodynamically tolerated ventricular tachycardia require implantable cardioverter defibrillators. Circulation 2007; 116: 1196–1203.
- Almendral J, Josephson ME. All patients with hemodynamically tolerated postinfarction ventricular tachycardia do not require an implantable cardioverter-defibrillator. Circulation 2007; 116: 1204–1212.
- Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997; 336: 1629–1633.
- de Bakker JM, Coronel R, Tasseron S, et al. Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol 1990; 15: 1594–1607.
-
de Bakker JM, van Capelle FJ, Janse MJ, et al. Macroreentry in the infarcted human heart: the mechanism of ventricular tachycardias with a “focal” activation pattern. J Am Coll Cardiol 1991; 18: 1005–1014.
10.1016/0735-1097(91)90760-7 Google Scholar
- Hargrove WC, III, Miller JM, Vassallo JA, Josephson ME. Improved results in the operative management of ventricular tachycardia related to inferior wall infarction. Importance of the annular isthmus. J Thorac Cardiovasc Surg 1986; 92: 726–732.
- Sosa E, Scanavacca M, d'Avila A, Oliveira F, Ramires JA. Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction. J Am Coll Cardiol 2000; 35: 1442–1449.
- Pogwizd SM, McKenzie JP, Cain ME. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 1998; 98: 2404–2414.
- Hsia HH, Marchlinski FE. Characterization of the electroanatomic substrate for monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy. Pacing Clin Electrophysiol 2002; 25: 1114–1127.
- Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G, Epstein LM. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy: the importance of low-voltage scars. J Am Coll Cardiol 2004; 43: 1834–1842.
- Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48: 1977–1985.
- Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51: 2414–2421.
- Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure [MERIT-HF]. Lancet 2001; 353: 2001–2007.
- Anonymous. The Cardiac Insufficiency Bisoprolol Study II [CIBIS-II]: a randomised trial. Lancet 1999; 353: 9–13.
- Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival [COPERNICUS] study. Circulation 2002; 106: 2194–2199.
- Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–237.
- Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151–2158.
- Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988; 318: 129–133.
- Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270–276.
- Reithmann C, Ulbrich M, Hahnefeld A, Huber A, Matis T, Steinbeck G. Analysis during sinus rhythm and ventricular pacing of reentry circuit isthmus sites in right ventricular cardiomyopathy. Pacing Clin Electrophysiol 2008; 31: 1535–1545.
- Corrado D, Basso C, Leoni L, et al. Three-dimensional electroanatomical voltage mapping and histologic evaluation of myocardial substrate in right ventricular outflow tract tachycardia. J Am Coll Cardiol 2008; 51: 731–739.
- Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competative athletes: analysis of 1866 deaths in the United States. Circulation 2009; 119: 1085–1092.
- Caselli S, Pelliccia A, Maron M, et al. Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hypertrophy by means of three-dimensional echocardiography. Am J Cardiol 2008; 102: 616–620.
- Martin M, Reguero JJ, Castro MG, et al. Hypertrophic cardiomyopathy and athletes heart: a tale of two entities. Eur J Echocardiogr 2009; 10: 151–153.
- Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice. Heart 2008; 94: 1269–1275.
- Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873–879.
- Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 2044–2051.
- Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778–1785.
- Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41: 315–321.
- Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118: 1541–1549.
- Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561–1567.
- Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995; 332: 1058–1064.
- Scott CL, Iyasu S, Rowley D, Atrash HK. Postneonatal mortality surveillance – United States, 1980–1994. MMWR 1998; 47: 15–30.
- Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 1998; 32: 245–251.
- Almahmeed W, Haykowski M, Boone J, Kavanagh-Gray D, Human D, Macdonald I. Congenitally corrected transposition of the great arteries and exercise-induced ventricular tachycardia. Can J Cardiol 1996; 12: 526–528.
- Fontaine JM, Kamal BM, Sokil AB, Wolf NM. Ventricular tachycardia: a life-threatening arrhythmia in a patient with congenitally corrected transposition of the great arteries. J Cardiovasc Electrophysiol 1998; 9: 517–522.
- Obioha-Ngwu O, Milliez P, Richardson A, Pittaro M, Josephson ME. Ventricular Tachycardia in Ebstein's Anomaly. Circulation 2001; 104E: 92–94.
- Vetter VL, Horowitz LN. Electrophysiologic residua and sequelae of surgery for congenital heart defects. Am J Cardiol 1982; 50: 588–604.
- Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol 1997; 30: 1368–1373.
- Gatzoulis MA, Till JA, Redington AN. Depolarization-repolarization inhomogeneity after repair of tetralogy of Fallot. The substrate for malignant ventricular tachycardia? Circulation 1997; 95: 401–404.
- Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000; 356: 975–981.
- Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation 1995; 92: 231–237.
- Gatzoulis MA, Elliott JT, Guru V, et al. Right and left ventricular systolic function late after repair of tetralogy of Fallot. Am J Cardiol 2000; 86: 1352–1357.
- Lillehei CW, Cohen M, Warden HE, et al. Direct vision intracardiac surgical correction of the tetralogy of Fallot, pentalogy of Fallot, and pulmonary atresia defects; report of first ten cases. Ann Surg 1955; 142: 418–442.
- Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart 2008; 94: 211–216.
- Hooft van Huysduynen B, Henkens IR, Swenne CA, et al. Pulmonary valve replacement in tetralogy of Fallot improves the repolarization. Int J Cardiol 2008; 124: 301–306.
- Oosterhof T, Vliegen HW, Meijboom FJ, Zwinderman AH, Bouma B, Mulder BJ. Long-term effect of pulmonary valve replacement on QRS duration in patients with corrected tetralogy of Fallot. Heart 2007; 93: 506–509.
- Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation 2001; 103: 2489–2494.
- Zahka KG, Horneffer PJ, Rowe SA, et al. Long-term valvular function after total repair of tetralogy of Fallot. Relation to ventricular arrhythmias. Circulation 1988; 78: III 14–19.
- Matsuoka S, Akita H, Hayabuchi Y, et al. Abnormal signal averaged ECG after surgical repair of tetralogy of Fallot – a combined analysis in the time and frequency domain. Jap Circ J 1993; 57: 841–850.
- Brili S, Aggeli C, Gatzoulis K, et al. Echocardiographic and signal averaged ECG indices associated with non-sustained ventricular tachycardia after repair of tetralogy of fallot. Heart 2001; 85: 57–60.
- Butera G, Bonnet D, Sidi D et al. Patients operated for tetralogy of fallot and with non-sustained ventricular tachycardia have reduced heart rate variability. Herz 2004; 29: 304–309.
- Cheung MM, Weintraub RG, Cohen RJ, Karl TR, Wilkinson JL, Davis AM. T wave alter-nans threshold late after repair of tetralogy of Fallot. J Cardiovasc Electrophysiol 2002; 13: 657–661.
- Folino AF, Russo G, Bauce B, Mazzotti E, Daliento L. Autonomic profile and arrhythmic risk stratification after surgical repair of tetralogy of Fallot. Am Heart J 2004; 148: 985–989.
- Janousek J, Paul T, Bartakova H. Role of late potentials in identifying patients at risk for ventricular tachycardia after surgical correction of congenital heart disease. Am J Cardiol 1995; 75: 146–150.
- Perloff JK, Middlekauf HR, Child JS, Stevenson WG, Miner PD, Goldberg GD. Usefulness of post-ventriculotomy signal averaged electrocardiograms in congenital heart disease. Am J Cardiol 2006; 98: 1646–1651.
- Russo G, Folino AF, Mazzotti E, Rebellato L, Daliento L. Comparison between QRS duration at standard ECG and signal-averaging ECG for arrhythmic risk stratification after surgical repair of tetralogy of fallot. J Cardiovasc Electrophysiol 2005; 16: 288–292.
- van den Berg J, de Bie S, Meijboom FJ, et al. Changes during exercise of ECG intervals related to increased risk for ventricular arrhythmia in repaired tetralogy of Fallot and their relationship to right ventricular size and function. Int J Cardiol 2008; 124: 332–338.
- Lucron H, Marcon F, Bosser G, Lethor JP, Marie PY, Brembilla-Perrot B. Induction of sustained ventricular tachycardia after surgical repair of tetralogy of Fallot. Am J Cardiol 1999; 83: 1369–1373.
- Chandar JS, Wolff GS, Garson A, Jr, et al. Ventricular arrhythmias in postoperative tetralogy of Fallot. Am J Cardiol 1990; 65: 655–661.
- Alexander ME, Walsh EP, Saul JP, Epstein MR, Triedman JK. Value of programmed ventricular stimulation in patients with congenital heart disease. J Cardiovasc Electrophysiol 1999; 10: 1033–1044.
- Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 2000; 109: 1994–2000.
- Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation 2008; 117: 363–370.
- Dore A, Santagata P, Dubuc M, Mercier LA. Implantable cardioverter defibrillators in adults with congenital heart disease: a single center experience. Pacing Clin Electrophysiol 2004; 27: 47–51.
- Misaki T, Tsubota M, Watanabe G, et al. Surgical treatment of ventricular tachycardia after surgical repair of tetralogy of Fallot. Relation between intraoperative mapping and histological findings. Circulation 1994; 90: 264–271.
- Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation 2007; 116: 2241–2252.
- Morwood JG, Triedman JK, Berul CI, et al. Radiofrequency catheter ablation of ventricular tachycardia in children and young adults with congenital heart disease. Heart Rhythm 2004; 1: 301–308.
- Kriebel T, Saul JP, Schneider H, Sigler M, Paul T. Noncontact mapping and radiofrequency catheter ablation of fast and hemodynamically unstable ventricular tachycardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol 2007; 50: 2162–2168.
- Gonska BD, Cao K, Raab J, Eigster G, Kreuzer H. Radiofrequency catheter ablation of right ventricular tachycardia late after repair of congenital heart defects. Circulation 1996; 94: 1902–1908.
- Chinushi M, Aizawa Y, Kitazawa H, Takahashi K, Washizuka T, Shibata A. Clockwise and counter-clockwise circulation of wavefronts around an anatomical obstacle as one mechanism of two morphologies of sustained ventricular tachycardia in patients after a corrective operation of tetralogy of Fallot. Pacing Clin Electrophysiol 1997; 20: 2279–2281.
-
Horton RP, Canby RC, Kessler DJ, et al. Ablation of ventricular tachycardia associated with tetralogy of Fallot: demonstration of bidirectional block. J Cardiovasc Electrophysiol 1997; 8: 432–435.
10.1111/j.1540-8167.1997.tb00808.x Google Scholar
- Amarasena NL, Pillai RP, Forfar JC. Atypical ventricular tachycardia and syncope with left coronary artery origin from the right coronary sinus. Br Heart J 1993; 70: 391–392.
- Daliento L, Fasoli G, Mazzucco A. Anomalous origin of the left coronary artery from the anterior aortic sinus: role of echocardiography. Int J Cardiol 1993; 38: 89–91.
- Papadopoulos DP, Economou CK, Moyssakis I, Votteas VE. Anomalous left coronary artery arising from the right sinus of valsalva as a cause of ventricular tachycardia. Acta Cardiol 2005; 60: 65–67.
- Facciorusso A, Lanna P, Vigna C, et al. Anomalous origin of the left coronary artery from the pulmonary artery in an elderly patient, football player in youth. J Cardiovasc Med 2008; 9: 1066–1069.
- Iga K, Hori K, Matsumura T, Gen H. Anomalous origin of left coronary artery from pulmonary artery in a 54-year-old woman presenting ventricular tachycardia from anteroseptal scar. Jap Circ J 1993; 57: 837–839.
- Coumel P, Fidelle J, Lucet V, Attuel P, Bouvrain Y. Catecholamine-induced severe ventricular arrhythmias with Adams–Stokes syndrome in children: report of four cases. Br Heart J 1978; 40(suppl): 28–37.
- Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512–1519.
- Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999; 34: 2035–2042.
- Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene [hRyR2] underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196–200.
- Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69–74.
- Laitinen PJ, Swan H, Kontula K. Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Genet 2003; 11: 888–891.
- Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13–21. Circulation 2001; 103: 2822–2827.
- Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69: 1378–1384.
- Lahat H, Pras E, Eldar M. A missense mutation in CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Ann Med 2004; 1: 87–91.
- Song L, Alcalai R, Arad M, et al. Calsequestrin 2 [CASQ2] mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2007; 117: 1814–1823.
- Katz G, Arad M, Eldar M. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond. Curr Probl Cardiol 2009; 34: 9–43.
- Nam GB, Burashnikov A, Antzelevitch C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation 2005; 111: 2727–2733.
- Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4: 675–678.
- Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66–70.
- Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4: 1149–1154.
- Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 2008; 358: 2024–2029.
- Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multi-center report. J Am Coll Cardiol 1992; 20: 1391–1396.
- Brugada J, Brugada P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997; 8: 325–331.
- Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659–670.
- Antzelevitch C, Brugada P, Brugada J, Brugada R. Brugada syndrome: from cell to bedside. Curr Probl Cardiol 2005; 30: 9–54.
- Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96: 2595–2600.
- Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105: 1342–1347.
- Brugada J, Brugada P, Brugada R. The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death–the Brugada syndrome. Europace 1999; 1: 156–166.
- Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002; 105: 73–78.
- Kasanuki H, Ohnishi S, Ohtuka M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997; 95: 2277–2285.
- Mizumaki K, Fujiki A, Tsuneda T, et al. Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004; 15: 667–673.
- Sangwatanaroj S, Chaichana T. The temporal variations of presumptive sudden death of Thai people in Singapore and Taiwan. J Med Assoc Thai 2006; 89 (suppl 3): S213–217.
- Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998; 97: 457–460.
- Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101: 510–515.
- Brugada R, Brugada P, Brugada J. Electrocardiogram interpretation and class I blocker challenge in Brugada syndrome. J Electrocardiol 2006; 39 (4 suppl): S115–115.
- Brugada J, Brugada P, Brugada R. The ajmaline challenge in Brugada syndrome: a useful tool or misleading information? Eur Heart J 2003; 24: 1085–1086.
- Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong P, Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 2001; 22: 2290–2296.
- Shimizu W, Matsuo K, Takagi M, et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 2000; 11: 396–404.
- Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293–296.
- Brugada P, Brugada R, Brugada J, Geelen P. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol 1999; 83: 11.
- Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108: 3092–3096.
- Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006; 114: 2317–2324.
- Shimizu W, Antzelevitch C, Suyama K, et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000; 11: 1320–1329.
- Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999; 10: 1301–1312.
- Haissaguerre M, Extramiana F, Hocini MC et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003; 108: 925–928.
- Brugada P, Brugada R, Brugada J. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation 2005; 112: 279–292.
- Brugada P, Brugada R, Mont L, Rivero M, Geelen P, Brugada J. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol 2003; 14: 455–457.
- Eckardt L, Probst V, Smits JP, et al. Long-term prognosis of individuals with right pre-cordial ST-segment-elevation Brugada syndrome. Circulation 2005; 111: 257–263.
- Jervell A, Lange-Nielesen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957; 54: 59–68.
- Dessertenne F, Coumel P, Fabiato A. Ventricular fibrillation and torsades de pointes. Cardiovasc Drugs Ther 1990; 4: 1177–1182.
- Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89–95.
- Thottathil P, Acharya J, Moss AJ, et al. International Long QT Syndrome Investigative Group. Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta[2] agonists. Am J Cardiol 2008; 102: 871–874.
- Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 2008; 19: 1289–1293.
- Shimizu W, Antzelevitch C. Effects of a K[[H11001]] channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000; 102: 706–712.
- Moss AJ, Liu JE, Gottlieb S, Locati EH, Schwartz PJ, Robinson JL. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation 1991; 84: 1524–1529.
- Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Lancet 1996; 348: 7–12.
- Køber L, Bloch Thomsen PE, Møller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000; 356: 2052–2058.
- Altin T, Ozcan O, Turhan S, et al. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 2007; 23: 907–908.
- Koh KK, Rim MS, Yoon J, Kim SS. Torsade de pointes induced by terfenadine in a patient with long QT syndrome. J Electrocardiol 1994; 27: 343–346.
- Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004; 45: 371–377.
- Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–1782.
- Traebert M, Dumotier B. Antimalarial drugs: QT prolongation and cardiac arrhythmias. Expert Opin Drug Saf 2005; 4: 421–431.
- Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience [ROLE]. J Am Coll Cardiol 2007; 49: 1027–1034.
- Inoue H, Zipes DP. Cocaine-induced supersensitivity and arrhythmogenesis. J Am Coll Cardiol 1988; 11: 867–874.
- Rouleau F, Asfar P, Boulet S et al. Transient ST segment elevation in right precor-dial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001; 12: 61–65.
- Soni S, Gandhi S. Flecainide overdose causing a Brugada-type pattern on electrocardiogram in a previously well patient. Am J Emerg Med 2009; 27: 375.
- Bebarta VS, Summers S. Propofol-induced Brugada electrocardiographic pattern. Crit Care Nurse 2008; 28: 23.
- Anderson JL, Hallstrom AP, Epstein AE, et al. Design and results of the antiarrhythmics versus implantable defibrillators [AVID] registry. Circulation 1999; 99: 1692–1699.
-
Zipes DP, Miles WM. Assessment of the patient with cardiac arrhythmia. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside, 4th edn. Saunders, Philadelphia, 2004: 759.
10.1016/B0-7216-0323-8/50085-3 Google Scholar
- Zimetbaum P, Josephson ME. Evaluation of patients with palpitations. N Engl J Med 1998; 338: 1369–1373.
- Calkins H, Shyr Y, Frumin H, Schork A, Morady F. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. Am J Med 1995; 98: 365–373.
- Mittal S, Iwai S, Stein KM, Markowitz SM, Slotwiner DJ, Lerman BB. Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era. J Am Coll Cardiol 1999; 34: 1082–1089.
- Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, ed. Heart Disease: A textbook of cardiovascular medicine, 5th edn. WB Saunders Company, Philadelphia, 1997: 742–779.
- Kowey PR, Podrid PJ. Sudden cardiac death. In: Podrid PJ, Kowey PR, eds. Cardiac Arrhythmia: Mechanisms, Diagnosis and Management. Williams and Wilkins, Baltimore, 1995: 974–1003.
